June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
December 2025 in “Babcock University Medical Journal” CD27 and IL-35 can help diagnose alopecia areata linked to bacterial infections.
Baricitinib effectively regrows hair in severe alopecia areata cases.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “International Journal of Dermatology Research” Higher MPV and CRP levels may indicate more severe alopecia areata.
January 2025 in “Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)” An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.
December 2024 in “International Journal of Health Sciences and Research” Vitamin D is crucial for health, and deficiency can cause hair loss and other health issues.
December 2024 in “Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi” Both treatments are safe and effective, but anthralin may work better for some patients.
September 2024 in “South Eastern European Journal of Public Health” Alopecia areata patients have higher IgE and IL-13 levels, suggesting immune involvement.
August 2024 in “OSMANGAZİ JOURNAL OF MEDICINE” The visfatin GT genotype may increase the risk of Alopecia Areata.
July 2024 in “Egyptian Journal of Medical Human Genetics” These gene variations are not linked to alopecia areata in Egyptians.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
January 2024 in “International journal of homoeopathic sciences” Early intervention and patient education are crucial for managing alopecia areata.
December 2023 in “Research Square (Research Square)” These specific gene polymorphisms are not linked to Alopecia Areata in Egyptians.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
January 2023 in “Annals of Dermatology” Patients with a specific genetic variant have more severe alopecia areata and higher recurrence rates.
November 2022 in “SAS journal of medicine” There's no link between low iron levels and the hair loss condition, alopecia areata.
January 2022 in “The Egyptian Journal of Hospital Medicine” Higher IL-21 levels may help predict alopecia areata activity.
December 2021 in “Research Square (Research Square)” M-CSF-stimulated myeloid cells can cause alopecia areata in mice.
June 2018 in “The Medical Journal of Cairo University/The Medical Journal of Cairo University” Dermoscopy can quickly and reliably distinguish Tinea Capitis from Alopecia Areata by identifying specific hair patterns.
May 2018 in “White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)” Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.
Better models and evaluation methods for alopecia areata are needed.
October 2014 in “Journal of skin and stem cell” Elidel combined with tretinoin is more effective for treating alopecia areata than Elidel alone.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
20 citations
,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.